Replies to post #222604 on Biotech Values

[CT]

Hey DD, have you ever spoken to the difficulty of unseating a very entrenched incumbent (AGN/Botox) with respect to RVNC. I wonder what your thoughts are. I realize that there are a few differences with RT002, as this is a product not paid for by insurance, but can AGN employ tactics that slow RT002 uptake (ala ABBV/Humira and others)? Or are those games enabled by our convoluted drug payment system?

RVNC's valuation seems completely mis-aligned if they can take even moderate market share from Botox.

Or is my thinking off base on this? Thanks.

Disclosure: Long RVNC